Selvigaltin (GB1211), an orally accessible small molecule galectin-3 inhibitor developed for a remedy for liver fibrosis and cirrhosis, was evaluated to evaluate the effect of hepatic impairment on its pharmacokinetics and security to deal with regulatory specifications. Table four Statistical evaluation of dose proportionality of the pharmacokinetic parameters of GB1211 https://selvigaltin-oral-small-mo24689.blogthisbiz.com/46671574/the-5-second-trick-for-selvigaltin-galectin-3-inhibitor